SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus

REFERENCES

• Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. J Am Med Assoc. 1989;262:2708–2713.
   PubMed Web of Science ®Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329: 977–986.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–853.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177–269.
   Google Scholar
• Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;4:515–531.
   Google Scholar
• Wing RR, Lang W, Wadden TA, . The look ARG: benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–1486.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.
   PubMed Web of Science ®Google Scholar
• Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med. 2009;76:S4–S11.
   PubMedGoogle Scholar
• Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc. 2003;78:459–467.
   PubMed Web of Science ®Google Scholar
• Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32:S151–S156.
   PubMed Web of Science ®Google Scholar
• Schmittdiel JA, Uratsu CS, Karter AJ, . Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23:588–594.
   PubMed Web of Science ®Google Scholar
• Dokken B. The kidney as a treatment target for type 2 diabetes. Diabetes Spectrum. 2012;25:29–36.
   Google Scholar
• Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–1277.
   PubMed Web of Science ®Google Scholar
• Wright EM. Renal Na(+)-glucose co transporters. Am J Physiol Renal Physiol. 2001;280:F10–F18.
   PubMed Web of Science ®Google Scholar
• Hediger MA, Kanai Y, You G, Nussberger S. Mammalian ion-coupled solute transporters. J Physiol. 1995;482:7S–17S.
   PubMed Web of Science ®Google Scholar
• Chin E, Zhou J, Bondy C. Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. J Clin Invest. 1993;91:1810–1815.
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant. 2010;25:2041–2043.
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Learning from glycosuria. Diabetes. 2011;60: 695–696.
   PubMed Web of Science ®Google Scholar
• Valtin H. Tubular reabsorption. In: Schafer JA, James A, eds.Renal Function. Boston, MA: Little, Brown and Company; 1983.
   Google Scholar
• Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52:1147–1154.
   PubMed Web of Science ®Google Scholar
• Norton L, DeFronzo RA, Muhammad AA. Sodium–glucose co-transporter 2 tnhibition – a novel strategy for glucose control in type 2 diabetes. US Endocrinology. 2010;6(1):42–47.
   Google Scholar
• Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+/glucose cotransporter. Nature. 1987;330:379–381.
   PubMed Web of Science ®Google Scholar
• Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93:397–404.
   PubMed Web of Science ®Google Scholar
• Diez-Sampedro A, Hirayama BA, Osswald C, . A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci USA. 2003;100:11753–11758.
   PubMed Web of Science ®Google Scholar
• Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5:133–141.
   PubMed Web of Science ®Google Scholar
• Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 2010;28:101–109.
   Google Scholar
• Chin E, Zamah AM, Landau D, . Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology. 1997;138:1267–1275.
   PubMed Web of Science ®Google Scholar
• Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8:943–948.
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulin-dependent diabetes. Diabetes. 2005;54:3427–3434.
   PubMed Web of Science ®Google Scholar
• Freitas HS, Anhe GF, Melo KF, . Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008;149:717–724.
   PubMed Web of Science ®Google Scholar
• Freitas HS, D’Agord SB, da Silva RS, Okamoto MM, Oliveira-Souza M, Machado UF. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats. Nephron Physiol. 2007;105:42–51.
   Web of Science ®Google Scholar
• Yamagata K, Oda N, Kaisaki PJ, . Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384:455–458.
   PubMed Web of Science ®Google Scholar
• Pontoglio M, Sreenan S, Roe M, . Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest. 1998;101:2215–2222.
   PubMed Web of Science ®Google Scholar
• Pontoglio M, Prie D, Cheret C, . HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1:359–365.
   PubMed Web of Science ®Google Scholar
• Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol. 1994;266:F283–F290.
   PubMed Web of Science ®Google Scholar
• Dominguez JH, Song B, Maianu L, Garvey WT, Qulali M. Gene expression of epithelial glucose transporters: the role of diabetes mellitus. J Am Soc Nephrol. 1994;5:S29–S36.
   PubMed Web of Science ®Google Scholar
• Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30:125–129.
   PubMed Web of Science ®Google Scholar
• Han HJ, Lee YJ, Park SU, Lee JH, Taub M. High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol. 2004;288:F988–F996.
   Web of Science ®Google Scholar
• Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62:1279–1284.
   PubMed Web of Science ®Google Scholar
• Han S, Hagan DL, Taylor JR, . Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723–1729.
   PubMed Web of Science ®Google Scholar
• Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest. 1991;87:561–570.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, Bastein A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–2233.
   PubMed Web of Science ®Google Scholar
• Kipnes MS. Sodium–glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: a review of phase II and III trials. Clin Invest. 2010;1:145–156.
   Google Scholar
• Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123:133–143.
   PubMed Web of Science ®Google Scholar
• Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013;65(3):317–327.
   Google Scholar
• Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510–1515.
   PubMed Web of Science ®Google Scholar
• Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008;327:268–276.
   PubMed Web of Science ®Google Scholar
• Kennedy RL, Chokkalingam K, Farshchi HR. Nutrition in patients with type 2 diabetes: are low-carbohydrate diets effective, safe or desirable? Diabet Med. 2005;22:821–832.
   PubMed Web of Science ®Google Scholar
• Geerlings SE, Stolk RP, Camps MJ, . Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23:1737–1741.
   PubMed Web of Science ®Google Scholar
• Idris I, Donnelly R. Sodium–glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metabol. 2009;11:79–88.
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513–519.
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodiumglucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care. 2009;32:650–657.
   PubMed Web of Science ®Google Scholar
• Oku A, Ueta K, Arakawa K, . Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats. Jpn J Pharmacol. 2000;84:351–354.
   PubMedGoogle Scholar
• Katsuno K, Fujimori Y, Takemura Y, . Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323–330.
   PubMed Web of Science ®Google Scholar
• Kolodny EH, Kline R, Altszuler N. Effect of phlorizin on hepatic glucose output. Am J Physiol. 1962;202:149–154.
   PubMed Web of Science ®Google Scholar
• Oku A, Ueta K, Nawano M, . Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol. 2000;391: 183–192.
   PubMed Web of Science ®Google Scholar
• Leahy JL, Bonner-Weir S, Weir GC. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest. 1988;81: 1407–1414.
   PubMed Web of Science ®Google Scholar
• Olson LK, Redmon JB, Towle HC, Robertson RP. Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest. 1993; 92:514–519.
   PubMed Web of Science ®Google Scholar
• Nunoi K, Yasuda K, Adachi T, . Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol. 2002; 29:386–390.
   PubMed Web of Science ®Google Scholar